NASDAQ:IPSC Century Therapeutics (IPSC) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free IPSC Stock Alerts Notice: Trading of Century Therapeutics halted at 09:54 AM EST due to "LULD pause". $3.13 +0.08 (+2.62%) (As of 05:12 PM ET) Add Compare Share Share Today's Range$2.96▼$3.5750-Day Range$2.84▼$5.3252-Week Range$1.28▼$5.51Volume75,350 shsAverage Volume200,617 shsMarket Capitalization$202.89 millionP/E RatioN/ADividend YieldN/APrice Target$13.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Century Therapeutics alerts: Email Address Century Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside334.5% Upside$13.60 Price TargetShort InterestBearish7.62% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.06Based on 4 Articles This WeekInsider TradingSelling Shares$127,635 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.94) to ($2.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.42 out of 5 starsMedical Sector589th out of 910 stocksBiological Products, Except Diagnostic Industry99th out of 153 stocks 3.4 Analyst's Opinion Consensus RatingCentury Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCentury Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.62% of the float of Century Therapeutics has been sold short.Short Interest Ratio / Days to CoverCentury Therapeutics has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Century Therapeutics has recently increased by 0.61%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCentury Therapeutics does not currently pay a dividend.Dividend GrowthCentury Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IPSC. Previous Next 3.4 News and Social Media Coverage News SentimentCentury Therapeutics has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Century Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for IPSC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added Century Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Century Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $127,635.00 in company stock.Percentage Held by InsidersOnly 7.60% of the stock of Century Therapeutics is held by insiders.Percentage Held by Institutions50.20% of the stock of Century Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Century Therapeutics are expected to decrease in the coming year, from ($1.94) to ($2.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Century Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Century Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCentury Therapeutics has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Century Therapeutics Stock (NASDAQ:IPSC)Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.Read More IPSC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IPSC Stock News HeadlinesApril 23, 2024 | finance.yahoo.comCentury Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitApril 23, 2024 | globenewswire.comCentury Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Century Therapeutics Amidst Strong Financial Backing and Promising Clinical AdvancesApril 15, 2024 | americanbankingnews.comAnalysts Issue Forecasts for Century Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:IPSC)April 14, 2024 | uk.investing.comCentury Therapeutics shares target cut, retains OverweightApril 14, 2024 | americanbankingnews.comCentury Therapeutics (NASDAQ:IPSC) Stock Rating Reaffirmed by Piper SandlerApril 12, 2024 | msn.comCentury Therapeutics Gears Up to Conquer Highly Unmet Areas in Autoimmune Disease TreatmentsApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 12, 2024 | markets.businessinsider.comCentury Therapeutics: Hold Rating Justified Amid Strategic Acquisition and Ongoing Clinical TrialsApril 11, 2024 | globenewswire.comCentury Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade TherapeuticsApril 8, 2024 | globenewswire.comCentury Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual MeetingMarch 29, 2024 | finance.yahoo.comCentury Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash WiselyMarch 19, 2024 | markets.businessinsider.comStrong Buy Rating for Century Therapeutics Amid Promising CNTY-101 Developments and Market CatalystsMarch 19, 2024 | globenewswire.comCentury Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceMarch 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Century Therapeutics on Strong Clinical and Financial OutlookMarch 15, 2024 | finanznachrichten.deCentury Therapeutics, Inc.: Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdatesMarch 14, 2024 | investorplace.comIPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023March 14, 2024 | benzinga.comCentury Therapeutics: Q4 Earnings InsightsMarch 14, 2024 | globenewswire.comCentury Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdatesMarch 11, 2024 | msn.comCentury Therapeutics to Showcase Groundbreaking Cancer Research at AACR Annual Meeting 2024March 9, 2024 | finance.yahoo.comCentury Therapeutics Inc (IPSC) COO Adrienne Farid Sells 53,515 SharesMarch 5, 2024 | globenewswire.comCentury Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual MeetingFebruary 22, 2024 | investorplace.com3 Millionaire-Maker Under-$10 Stocks to Buy in February 2024February 15, 2024 | seekingalpha.comIPSC Century Therapeutics, Inc.February 14, 2024 | investing.comCentury Therapeutics Inc (IPSC)February 1, 2024 | finance.yahoo.comCentury Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceSee More Headlines Receive IPSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today4/23/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IPSC CUSIPN/A CIK1850119 Webwww.centurytx.com Phone267-817-5790FaxN/AEmployees152Year FoundedN/APrice Target and Rating Average Stock Price Target$13.60 High Stock Price Target$24.00 Low Stock Price Target$5.00 Potential Upside/Downside+345.9%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-136,670,000.00 Net Margins-6,115.12% Pretax Margin-6,030.96% Return on Equity-54.73% Return on Assets-31.15% Debt Debt-to-Equity RatioN/A Current Ratio9.92 Quick Ratio9.92 Sales & Book Value Annual Sales$2.23 million Price / Sales88.66 Cash FlowN/A Price / Cash FlowN/A Book Value$3.09 per share Price / Book0.99Miscellaneous Outstanding Shares64,820,000Free Float59,892,000Market Cap$197.70 million OptionableOptionable Beta1.33 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Adrienne Farid Ph.D. (Age 62)COO & Head of Early Development Comp: $650.66kMr. Brent Pfeiffenberger M.B.A.Pharm.D., CEO & DirectorMr. Douglas Carr CPAInterim Principal Financial Officer, Senior VP of Finance & Operations and SecretaryDr. Gregory Russotti Ph.D. (Age 57)Chief Technology & Manufacturing Officer Mr. Kenneth J. Dow J.D.Senior VP of General CounselDr. Shane Williams Ph.D.Chief People OfficerDr. Hyam I. Levitsky M.D. (Age 66)President of Research & Development Comp: $502.12kMichael Naso Ph.D.Senior VP of Cell EngineeringDr. Nick Trede M.D.Ph.D., Senior VP & Head of Clinical DevelopmentMore ExecutivesKey CompetitorsKodiak SciencesNASDAQ:KODCardiff OncologyNASDAQ:CRDFOptheaNASDAQ:OPTInnate PharmaNASDAQ:IPHAAcumen PharmaceuticalsNASDAQ:ABOSView All CompetitorsInsiders & InstitutionsAdrienne FaridSold 22,831 sharesTotal: $117,351.34 ($5.14/share)Abel Hall LLCBought 10,071 shares on 2/28/2024Ownership: 0.017%Avidity Partners Management LPBought 256,500 shares on 2/14/2024Ownership: 2.265%New York Life Investment Management LLCSold 2,694 shares on 2/6/2024Ownership: 0.167%Douglas CarrSold 643 sharesTotal: $2,469.12 ($3.84/share)View All Insider TransactionsView All Institutional Transactions IPSC Stock Analysis - Frequently Asked Questions Should I buy or sell Century Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Century Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IPSC shares. View IPSC analyst ratings or view top-rated stocks. What is Century Therapeutics' stock price target for 2024? 5 Wall Street research analysts have issued 12 month price objectives for Century Therapeutics' shares. Their IPSC share price targets range from $5.00 to $24.00. On average, they expect the company's stock price to reach $13.60 in the next year. This suggests a possible upside of 334.5% from the stock's current price. View analysts price targets for IPSC or view top-rated stocks among Wall Street analysts. How have IPSC shares performed in 2024? Century Therapeutics' stock was trading at $3.32 at the beginning of the year. Since then, IPSC stock has decreased by 5.7% and is now trading at $3.13. View the best growth stocks for 2024 here. When is Century Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our IPSC earnings forecast. How were Century Therapeutics' earnings last quarter? Century Therapeutics, Inc. (NASDAQ:IPSC) posted its quarterly earnings data on Thursday, March, 14th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.07. The company earned $0.27 million during the quarter, compared to the consensus estimate of $1.69 million. Century Therapeutics had a negative net margin of 6,115.12% and a negative trailing twelve-month return on equity of 54.73%. When did Century Therapeutics IPO? Century Therapeutics (IPSC) raised $201 million in an IPO on Friday, June 18th 2021. The company issued 10,600,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. How do I buy shares of Century Therapeutics? Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IPSC) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeHow to camouflage a factory of 53,000 workersStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
